Loading...
Loading...
ISI Group initiated its coverage on Qiagen
QGEN with a rating of Underweight and a $15 price target.
ISI Group commented, "We are initiating coverage on shares of Qiagen with an Underweight rating and a price target of $15.00, which on a forward basis equates to ~10x EV/EBITDA and ~14x operating EPS. Our thesis for QGEN is based on potential global research budget challenges translating into a muted outlook for the academic and biopharma segments, slowing growth in the HPV franchise, and the need for sustained R&D investments (companion diagnostic agreements) capping medium-term earnings growth."
Qiagen closed at $17.03 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in